BLUETTI to Release AC180, Making Another Breakthrough in Portable Power Station Area
Spring camping has gradually become popular in recent years, providing a precious chance for people to get rid of the hustle and bustle of urban life and have close contact with nature. However, most of their trips experienced mobile power shortages out there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005196/en/
(Photo: Business Wire)
BLUETTI, a market leader in the energy storage industry, is about to unveil a brand-new model. As a successor of the previous portable stations such as EB150 and EB240, AC180 is designed with a bunch of improvements that kit it up a notch, making it a well-deserved portable power station for emergency backup, sudden blackouts, excursions, and more.
Explore Outdoors with Great Capacity
To help elevate the off-grid lifestyle, BLUETTI equips AC180 with a 1800W constant output power and 1.152Wh capacity, covering almost all power demands of essentials at home or in the wild. Furthermore, AC 180 also comes with a Power Lifting Mode of 2.700W output to effortlessly run high-powered devices like kettles, hair dryers, microwaves, etc.
Besides, AC180 is updated with a 1,7-inch LCD display and bigger font size to make the power consumption and troubleshooting status more visualized and clearly.
Travel with Grab-and-go Power
Pack lighter, travel further. In view of portability, AC180 is ultra compact for effortless transportation as it measures 340mmｘ247mmｘ317mm (H x W x H) and weighs only 35kg. It does not occupy too much space of the truck on the way to the next campsite.
Recharge with High Speed
For outdoor enthusiasts looking for backup power for their camping or RV trips on the road, AC180 is sure to exceed their expectations. Even exploring off the beaten track far from the main grid, the reliable power source is always on call as AC180 supports up to 1.440W Turbo Charging, 0-80% SOC only takes about 45mins! Get it charged before packing up for the getaway, a large amount of power is ready to hit the road when you are.
Live with Uninterrupted Power Supply
Given the UPS system, there’s no need to worry about losing data or hardware damage in the event of a power outage since AC180 can automatically detect the blackout the moment it occurs and seamlessly switch over in 20ms that no one can even be aware of.
Constant Power with Peace of Mind
Keeping high security and longevity in mind, BLUETTI adopts safe and durable LiFePO4 battery cells and guarantees a worry-free warranty for as long as 5 years, which really sets it apart from most competitors throughout the market.
Remotely monitoring AC180 in real time is a no-brainer thanks to the intelligent BLUETTI APP. Now setting up working modes, checking the system conditions, and OTA updates can be done solely with fingertips.
“We’re dedicated to more innovations that’s a right fit for the increasing market demand. Our R&D team once envisioned a power station integrated with portability, capability, and cost performance, and now we’ve made it come true. AC180 has everything users could possibly need without costing an arm and a leg,” said James Ray, the marketing director of BLUETTI.
Availability
Though the debut price is not finally decided yet, it’s believed to be the most affordable power station that worth the wait.
About BLUETTI
From the very beginning, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for our homes and our world. That's why BLUETTI makes its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/ or follow BLUETTI on:
YouTube: https://www.youtube.com/c/bluettiofficial
Facebook: https://www.facebook.com/bluettipower.eu/
Twitter: https://twitter.com/bluetti_inc
Instagram: https://www.instagram.com/bluetti_europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005196/en/
Contact information
jacinda@bluetti.com
130 4085 7737
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom